Many millions of Americans suffer from episodic & chronic migraines including cluster headaches all resulting in an estimated 150 million workdays lost every year which in turn cost Americans over $10 Billion in direct costs, annually.

 

Medical science has attepted to "reset" chaotic signal impulse conduction in the Spenopalatine Ganglion (SPG) for over 100 years. SPG/V2 neuralgia has been linked to painful conditions such as episodic and chronic migraine, trigeminal neuralgia, upper plate dental pain, failed dental procedures and atypical facial neuropathies.

 

The simple procedure is effective in providing immediate and long-term relief from SPG/PPG and V2 related conditions (Central Dysautonomia).

 

The SpenoCath is an FDS registered Class-1 trans nasal drug delivery device that has been reported to provide procedural efficacy of over 50% reduction in VAS (Visual Analog Scale) for greater than 80% of their patients. Exceptional patient tolerance and no reported severe adverse events or reactions.

 

Most Insurance companies and Medicare cover the procedure. A typical SpenoCath procedure costs no more than one month of migraine meds but last three to four times longer.